Numerous studies have shown that RIPK1 inhibitors present a potential therapeutic alternative for the management of a wide variety of inflammatory and degenerative diseases in humans, including colitis, dermatitis, traumatic brain injury, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), etc. (5). Here, RIPK1 is linked to dermatitis.